KURA | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 23%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.66%

1 Month

-19.16%

3 Months

-54.73%

6 Months

-56.76%

1 Year

-35.28%

2 Year

-21.10%

Key data

Stock price

$8.86

P/E Ratio

0.00

DAY RANGE

$8.90 - $20.24

EPS

$0.00

52 WEEK RANGE

$9.02 - $24.17

52 WEEK CHANGE

-$37.69

MARKET CAP

1.614 B

YIELD

N/A

SHARES OUTSTANDING

76.634 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.44

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,335,572

AVERAGE 30 VOLUME

$2,168,654

Company detail

CEO: Troy E. Wilson
Region: US
Website: kuraoncology.com
Employees: 130
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.

KURA - Kura Oncology, Inc.